One Null Study Beats Two Positive Ones at the FTC

What does FTC Example 30 describe?

FTC's Example 30 describes a supplement marketer who did the science and still can't run the claim. The Federal Trade Commission — FTC for the rest of this page — lays out the scenario in its Health Products Compliance Guidance, published December 2022, as a straightforward test of an advertiser seeking to substantiate that a supplement will substantially reduce body fat. The file looks strong at first glance: "the advertiser has two controlled, double-blind studies showing a modest but statistically significant loss of fat" over a six-week period. That's not a testimonial reel or an in-vitro press release — it's the randomized, blinded evidence FTC actually asks marketers to go collect, and by itself it would clear most internal compliance reviews without a second look.

Then FTC adds a third study, and the claim collapses.

We counted the trial designs FTC stacks against each other in this example: two six-week studies showing a positive result, and one twelve-week study showing none. The third trial is "an equally well-controlled, double-blind 12-week study showing no statistically significant difference" against control. It ran twice as long as either positive trial and used the same design rigor. FTC's example treats that third result as decisive, not as an outlier the advertiser gets to explain away.

Why does the FTC weigh totality rather than count studies?

Because FTC's substantiation test asks whether the whole body of research supports a claim, not whether a majority of trials do. Most advertisers assume evidence works like a vote — more studies in your favor should outweigh fewer against you. FTC's totality standard rejects that arithmetic outright: a single, equally rigorous null result can outweigh two positive studies, regardless of the count on either side.

FTC's own language for the outcome is blunt: "Given the totality of the evidence, the claim is unsubstantiated." Two out of three studies running in the advertiser's favor doesn't survive that framing, because the test was never a tally in the first place.

This is the same logic that decides which aggressive claims still pass the substantiation line in supplement advertising — how the claim is worded matters far less than whether your full evidence file, positives and negatives together, actually backs it.

How does study duration affect which result carries weight?

Duration alone doesn't decide the outcome in Example 30 — design rigor does. The null result happened to come from a twelve-week study, twice the length of either positive trial, but FTC credits it for matching the same randomized, controlled, double-blind design, not for simply running longer.

A longer observation window can still expose an effect that fades.

For a body-fat claim specifically, six weeks may only capture an early water-weight or appetite effect that a twelve-week study catches wearing off. FTC doesn't diagnose why the studies disagree in this example — only that they do, and that disagreement alone is enough to sink the claim once a comparably rigorous study contradicts it.

What does 'equally well-controlled' mean in this comparison?

"Equally well-controlled" means the null study meets the identical design bar as the positive ones: randomized, controlled, double-blind. That phrase does the real work in Example 30, because it closes off the easiest way to make an inconvenient result disappear — arguing it was simply a weaker study.

The same design-equivalence logic underlies a related FTC position, discussed in why ingredient studies do not substantiate your formula: a federal court required that trials run on the exact dosage and formulation actually sold, not on the individual ingredients tested separately, because ingredients can interact in ways that change the physiological outcome. Five studies on five separate ingredients isn't the same evidence as one study on the finished product you're selling.

Can an advertiser cite only the favorable studies?

No. FTC's guidance treats selective citation as a failure on its own, not just a symptom of thin evidence. An advertiser who cites the two six-week studies and leaves out the twelve-week null result hasn't presented an incomplete file — under Example 30's logic, that omission is itself the deception.

Hedged language doesn't fix a cherry-picked file either.

FTC's guidance runs a companion example — numbered 13 in the same document — about a cholesterol supplement advertised on preliminary research despite real limitations in the underlying studies; we could not verify the Commission's full stated conclusion for that example, because the passage was truncated in the source material we checked, and it needs to be confirmed against the guidance's complete text before anyone quotes a verdict from it. What's settled is Example 30's own math: two studies plus one that contradicts them, cited selectively, doesn't clear the bar.

How does this apply to body fat versus body weight claims?

Body fat and body weight aren't interchangeable endpoints, and FTC has litigated the difference directly. In FTC v. National Urological Group, the court held that "a study examining metabolic endpoints cannot determine whether weight loss will also occur" — a distinction that runs the same way between fat, weight, and any metabolic marker in between.

The mismatch shows up cleanly as a table of what each claim actually requires.

What evidence file would actually satisfy this standard?

A file that satisfies this standard reports every relevant trial on the exact claim, endpoint, dosage and formulation you're selling — including the ones that came out negative — and lets FTC weigh all of it together rather than the subset you'd prefer to lead with.

We checked how this evidence-file standard interacts with FDA's separate claim-type rules, and the two run on independent tracks. Even a claim that clears FDA's structure/function line while FTC still rules your ad still needs a file like this, because FDA's structure/function rule never asks whether the claim is true — only whether it names a disease. FTC is the one that asks whether the studies actually back it.

The cost of skipping this file isn't hypothetical. The neuropathy case that ended a supplement company started with claims that outran a comparable evidence gap, and it ended in a full ban on advertising or selling any dietary supplement at all.

• Randomized, controlled, double-blind human trials, matched to the specific claim being made.
• An endpoint that measures the thing you're claiming — weight for a weight claim, fat for a fat claim, not a proxy.
• Testing on the exact dosage and formulation sold, not ingredient-level studies stitched together after the fact.
• Disclosure of every relevant trial you're aware of, including negative ones — omission is its own violation under Example 30's logic.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Offers Targeting GLP-1 Users: The Side-Effect Economy, Best Nutra Affiliate Networks: Ranked by Offer Depth, Probiotic Weight Loss Offers: The Gut-Slim Ad Angle, Best GEOs for Nutra Offers in 2026: A Data Tier List, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.